Vertex Pharmaceuticals Inc / Ma: Form 10-Q for the period ended Sep 30, 2017
Filed with the SEC on Oct 30, 2017 and accepted by EDGAR at Oct 30, 2017, 21:15 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2017-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Research and development | 3 months2017-07-01 to 2017-09-30 | $454.9m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 9 months2017-01-01 to 2017-09-30 | $1.02bn | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months2017-07-01 to 2017-09-30 | $120.7m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2017-01-01 to 2017-09-30 | $361.3m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2017-07-01 to 2017-09-30 | −$326.0m | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2017-01-01 to 2017-09-30 | −$2.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months2017-07-01 to 2017-09-30 | −$125.9m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2017-01-01 to 2017-09-30 | −$117.6m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2017-07-01 to 2017-09-30 | −$103.0m | us-gaap:NetIncomeLoss |
| Net income | 9 months2017-01-01 to 2017-09-30 | $162.8m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2017-07-01 to 2017-09-30 | −$0.41 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2017-01-01 to 2017-09-30 | $0.64 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2017-07-01 to 2017-09-30 | −$0.41 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2017-01-01 to 2017-09-30 | $0.66 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2017-07-01 to 2017-09-30 | 250,268,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2017-01-01 to 2017-09-30 | 252,095,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2017-01-01 to 2017-09-30 | $617.4m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2017-01-01 to 2017-09-30 | $56.8m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | At period end2017-09-30 | $1.38bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2017-09-30 | $2.33bn | us-gaap:AssetsCurrent |
| Total assets | At period end2017-09-30 | $3.20bn | us-gaap:Assets |
| Current liabilities | At period end2017-09-30 | $710.7m | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2017-09-30 | $1.40bn | us-gaap:Liabilities |
| Shareholders' equity | At period end2017-09-30 | $1.79bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0000875320-17-000060. Last ingested by Listed: Nov 6, 2026, 12:56 ET. Listed shows no prices and gives no investment advice.